Analytical methods
Genomic sequencing of coding regions, eventually multiple ligationdependent analysis (MLPA) for detection of genomic rearrangements and large deletions.
Analytical validation
Direct sequencing of both DNA strands; verification of sequence and MLPA results with second DNA extraction or second PCR or hybridisation (MLPA).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Prevalence about 1:5000-1:100 000 depending on EDS type. 1,2 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable for most EDS types except for EDS type VIA which is most prevalent in the Middle East.
Diagnostic setting
Comment: Prenatal diagnosis is rarely requested for Ehlers-Danlos syndrome.
TEST CHARACTERISTICS
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Nearly 100%, if a deletion/duplication diagnostic test has been made for genes with the possibility of a rearrangement.
2.2 Analytical specificity (proportion of negative tests if the genotype is not present) Nearly 100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependant on variable factors such as age or family history. In such cases a general statement should be given, even if only a quantification can be made case by case.
It is 50% for EDS type I/II (COL5A1 and COL5A2 genes) which is genetically heterogeneous with additional, still unknown gene loci.
It is 95% for EDS type IV (COL3A1 gene), EDS types VIIA and VIIB (COL1A1 and COL1A genes, respectively) as well as EDS type VIA (PLOD1 gene). 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (please describe) Yes. In many cases, the genetic diagnostics contribute substantially to classifaction of EDS type if clinical, biochemical, and ultrastructural findings are not fully informative. Recognising clinical symptoms as belonging to the Ehlers-Danlos syndrome and classifying them as a given EDS type is prerequisite for clinical prognosis, specific therapy, and official acceptance as severe handicap. In children with a tendency to haematomas, a suspicion of child abuse may be alleviated through the correct diagnosis of EDS type. The correct diagnosis will end a diagnostic odyssey and the unwarranted suspicion of hypochondria, and the appropriate patient organisation can now be approached.
